Phenylalanine
- Generic Name
- Phenylalanine
- Brand Names
- Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinimix 2.75/5, Clinimix E 2.75/5, Clinisol 15, Freamine 6.9, Freamine III 10, Hepatamine 8, Nephramine, Olimel, Periolimel, Plenamine, Premasol, Primene, Procalamine 3, Prosol, Travasol 10, Trophamine 10 %
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11NO2
- CAS Number
- 63-91-2
- Unique Ingredient Identifier
- 47E5O17Y3R
- Background
Phenylalanine is an essential aromatic amino acid that is a precursor of melanin, dopamine, noradrenalin (norepinephrine), and thyroxine.
- Indication
L-phenylalanine may be helpful in some with depression. It may also be useful in the treatment of vitiligo. There is some evidence that L-phenylalanine may exacerbate tardive dyskinesia in some schizophrenic patients and in some who have used neuroleptic drugs.
- Associated Therapies
- Amino acid supplementation
F 18 T807 PET (Positron Emission Tomograph )Scan for HIV Infected & Uninfected
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- Tammie L. S. Benzinger, MD, PhD
- Target Recruit Count
- 60
- Registration Number
- NCT03279523
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Bovine Lactoferrin Versus Ferrous Sulphate In The Treatment Of Iron Deficiency Anemia During Pregnancy
Phase 4
- Conditions
- Anemia During Pregnancy
- Interventions
- Dietary Supplement: L (lactoferrin)
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2018-07-09
- Lead Sponsor
- Abdelwahed, Mai Mahmoud Mohamed, M.D.
- Target Recruit Count
- 130
- Registration Number
- NCT03202615
- Locations
- 🇪🇬
Mai Mahmoud Mohamed, Alexandria, Egypt
Study to Assess the Taste Profile of Different ALS-008176 Oral Liquid Formulations in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Formulation A (ALS-008176)Drug: Formulation G1 (ALS-008176)Drug: Formulation B (ALS-008176)Drug: Formulation G2 (ALS-008176)Drug: Formulation C (ALS-008176)Drug: Formulation G3 (ALS-008176)Drug: Formulation H1 (ALS-008176)Drug: Formulation E (ALS-008176)Drug: Formulation H2 (ALS-008176)Drug: Formulation H3 (ALS-008176)
- First Posted Date
- 2016-06-27
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 11
- Registration Number
- NCT02813460
Efficacy of Three Toothpastes Using an in Situ Caries Model
Not Applicable
Completed
- Conditions
- Dental Caries
- Interventions
- Drug: 0.3%ZnCl2, 0.5% sodium citrate, 1150ppm FOther: 0 ppm FDrug: 0.425 % w/w phytate,1150ppm FDrug: 0.85 % w/w phytate,1150ppm FDrug: 0.85 % w/w phytate,0.3%ZnCl2 0.5% sodium citrate, 1150ppm F
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 58
- Registration Number
- NCT02751320
- Locations
- 🇺🇸
GSK Investigational Site, Indianapolis, Indiana, United States
F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)
- First Posted Date
- 2016-03-14
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Tammie L. S. Benzinger, MD, PhD
- Registration Number
- NCT02707978
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Study to Evaluate Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Formulation ADrug: Formulation M1Drug: Formulation BDrug: Formulation M2Drug: Formulation CDrug: Formulation M3Drug: Formulation N1Drug: Formulation EDrug: Formulation N2Drug: Formulation N3
- First Posted Date
- 2015-04-27
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 12
- Registration Number
- NCT02426632
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- First Posted Date
- 2015-04-10
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Tammie L. S. Benzinger, MD, PhD
- Target Recruit Count
- 900
- Registration Number
- NCT02414347
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E)
Completed
- Conditions
- Progressive Posterior Cortical Dysfunction (PPCD)Alzheimer Disease
- Interventions
- First Posted Date
- 2015-04-10
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- Tammie L. S. Benzinger, MD, PhD
- Target Recruit Count
- 20
- Registration Number
- NCT02414282
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project)
- Conditions
- Alzheimer Disease
- Interventions
- First Posted Date
- 2015-04-10
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 130
- Registration Number
- NCT02414178
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
A Crossover Study to Evaluate Relative Bioavailability of Simeprevir Age-appropriate Oral Formulation Candidates Compared With 150-milligram (mg) Oral Capsule in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Treatment ADrug: Treatment BDrug: Treatment EDrug: Treatment C
- First Posted Date
- 2015-03-11
- Last Posted Date
- 2017-09-07
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 48
- Registration Number
- NCT02385071
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath